<DOC>
	<DOCNO>NCT02745392</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center , parallel-group study design compare safety efficacy range dose ZP-Zolmitriptan intracutaneous microneedle system placebo .</brief_summary>
	<brief_title>Safety Efficacy ZP-Zolmitriptan Intracutaneous Microneedle Systems Acute Treatment Migraine</brief_title>
	<detailed_description>This randomize , double-blind , multi-center , parallel group study design compare safety efficacy range dose ZP-Zolmitriptan intracutaneous microneedle system placebo . Subjects consent meet entry criterion randomize one four blind treatment group . There screen period 1 week , follow run-in period record migraine activity . The run-in period determine eligibility randomization , plan 4 week duration may extend additional 4 week accommodate scheduling . Qualified subject randomize double-blind treatment period Day 0 8 week confirm treat qualify migraine . Using eDiary confirm experience qualified migraine , subject self-administer patch patch continue respond question eDiary 48 hour post treatment administration .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Greater 1 year history episodic , acute migraine ( without aura ) onset prior 50 year age . Diagnosis must comply International Headache Society ( IHS ) diagnostic criterion . Diagnostic criterion must include history least five attack attribute disorder include follow criterion : 1 . Headache attack last 472 hour ( untreated unsuccessfully treat ) 2 . Headache least two follow characteristic : ( ) unilateral location ( ii ) pulsating quality ( iii ) moderate severe pain intensity ( iv ) aggravation cause avoidance routine physical activity ( e.g. , walk climb stair ) c ) During headache least one following : ( ) nausea and/or vomiting ( ii ) photophobia phonophobia Migraine history 6month period prior runin period must include : 28 migraine per month 10 headache day per month Women childbearing potential must pregnant , must agree avoid pregnancy trial , must use acceptable method birth control duration trial . No significant ECG finding , define : 1. ischemic change 2 . Qwaves least two contiguous lead , 3. clinically significant intraventricular conduction abnormality ( leave bundle branch block WolfParkinsonWhite syndrome ) , 4. clinically significant arrhythmia ( e.g. , current atrial fibrillation ) Able understand operation electronic diary able apply demo study drug patch . Contraindication triptans Use prohibit concomitant medication within 10 day Runin Period History hemiplegic basilar migraine Participation another investigational trial 30 day prior Runin Period study Previous participation clinical trial ZPZolmitriptan Diagnosis cancer ( noninvasive skin cancer ) within 5 year prior Runin Period History unstable psychiatric illness require medication hospitalization 12 month prior Runin Period Subjects know allergy sensitivity zolmitriptan derivative formulation Subjects know allergy sensitivity adhesive Planned participation activity cause inflammation , irritation , sunburn , lesion , tattoo intend application site two week prior screen last day study participation Use opiate analgesic barbiturates frequently one day/week Women pregnant , breastfeed plan pregnancy study Clinically significant liver disease Clinically significant kidney disease History coronary artery disease ( CAD ) , coronary vasospasm ( include Prinzmetal 's angina ) , aortic aneurysm , peripheral vascular disease ischemic disease ( e.g. , ischemic bowel syndrome Raynaud 's syndrome ) Three follow CAD risk factor : Current tobacco use Hypertension receive antihypertensive medication treatment hypertension Hyperlipidemia prescribe anticholesterol treatment Family history premature coronary artery disease ( &lt; 55 year age male first degree relative &lt; 65 year age female first degree relative ) Diabetes mellitus History cerebral vascular accident , transient ischemic attack , seizure Hospitalization within 30 day prior Runin Period Any household member currently participate ZPZolmitriptan study relatives site staff Any reason believe compliance study requirement completion evaluation require study possible History current abuse dependence alcohol drug would interfere adherence study requirement Any clinically relevant abnormal finding physical exam , vital sign laboratory test , opinion Investigator , may put subject risk To eligible Treatment , subject must continue meet eligibility criterion follow criterion observe Runin Period : 1 . An average least two qualify migraine per 28day period 2 . No 10 headache day last 28 day prior randomization 3 . Demonstrated ability properly use eDiary apply demo study drug patch 4 . Confirmation continue good general health , stable nonserious disease opinion Investigator place subject risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>migraine</keyword>
	<keyword>migraine headache</keyword>
	<keyword>acute migraine</keyword>
	<keyword>acute migraine headache</keyword>
</DOC>